Implementing Technology and Medication Assisted Treatment and Team

Implementing Technology and Medication Assisted Treatment and Team

Implementing Technology and Medication Assisted Treatment and Team Training in Rural Colorado Behavioral Health Provider Training Module 3: Pharmacology of Buprenorphine and Other Drugs Copyright 2018 Regents of the University of Colorado. All Rights Reserved. For permission to use content for purposes other than IT MATTTRs Practice Team Training, please contact [email protected]

What are opioids? Drugs that bind to the opioid receptors Mu, Kappa, and Delta Can be produced naturally by plants or derivatives of naturallyoccurring compounds (opiates) Morphine, codeine Heroin: 10x more potent than morphine Can be synthetic or semisynthetic drugs (opioids) Methadone Fentanyl: 100x more potent than morphine

Mu Receptor Mediates Opioid Effects Euphoria, sedation, relaxation, pain and anxiety relief, sleepiness Chemical opioids stimulate the receptor much more powerfully than the bodys natural (endogenous) opioids Agonist (here, the opioid) activates the receptor Antagonist blocks the receptor

All chemical opioids may cause physical dependence and addiction. Clinical Applications of Opioids In clinical settings as analgesics. Highly reinforcing. High potential for abuse. Opioid Tolerance and Physical Dependence Both tolerance and physical dependence are physiological adaptations to chronic opioid exposure.

Tolerance: Increased dosage needed to produce specific effect. Develops readily for central nervous system and respiratory depression. Physical Dependence: Signs and symptoms of withdrawal by abruptly stopping the opioid, rapid dose reduction, or administration of antagonist

Opioid Withdrawal: Diagnosis (DSM5) A) Cessation or reduction of opioid use that was substantial and protracted OR after administration of an opioid antagonist following a period of opioid use. B ) Three of the following: Dysphoric mood Nausea or vomiting Muscle aches Insomnia Diarrhea Yawning

Fever Lacrimation or rhinorrhea Pupillary dilation, piloerection, or sweating C) Impaired functioning not explained by another condition. D) Duration and severity of opioid withdrawal are dependent on individual's drug of abuse and degree of dependence. Opioid Withdrawal: using the

Clinical Opiate Withdrawal Scale (COWS) Opioid Withdrawal: Types Spontaneous: Physically dependent individual suddenly stops or significantly decreases opioid usage. Precipitated: More intense than spontaneous and has much faster onset. Full agonist (e.g., heroin) displaced from receptors by antagonist (e.g., naloxone). Protracted: Withdrawal symptoms or other symptoms continue past the time expected for acute withdrawal, and sometimes last for months or years.

Medically supervised: Withdrawal through tapering How Addiction Hijacks the Brain How does buprenorphine work? Activity What does it do? Activate (agonist) vs. block (antagonist) Affinity How tightly it binds

to the mu receptor. Buprenorphine Partial mu-opioid agonist Metabolism In liver with N-dealkylation by cytochrome P450 3A4 enzyme system into an active metabolite norbuprenorphine Norbuprenorphine undergoes further glucuronidation Elimination Excreted in feces (70%) and urine (30%)

Mean elimination half-life = 37 hours Commercial screening urine drug test for parent compound and metabolite Does NOT show as opiate positive on standard drug screen How Buprenorphine Is Supplied? Buprenorphine single ingredient or combined with naloxone. The following formulations are available: Buprenorphine/naloxone (Suboxone) for treatment of OUD Monotherapy buprenorphine for treatment of OUD, including implant form Formulations of buprenorphine for treating pain (Buprenex, Butrans, Belbuca )

Common Buprenorphine Side Effects Safe when used as indicated Side effects are rare, usually minor, and similar to side effects of other opioids. Headaches Pain Nausea and vomiting Constipation Insomnia

Sweating Numb mouth and painful tongue Withdrawal syndrome (consider whether precipitated) Drug Interactions Known interactions with buprenorphine or buprenorphine/naloxone combination include the following drug classes: Benzodiazepines (e.g., Xanax, Valium) Other CNS depressants (e.g., Ambien, Lunesta)

CYP3A4 inducers and inhibitors (e.g., Ketoconazole, Rifampicin) Non-benzodiazepine muscle relaxants (e.g., metaxalone) Anticholinergics (e.g., Cogentin) Psychostimulants (e.g., Adderall) Low Buprenorphine Overdose Risk Safe and efficacious in primary care setting Ceiling effect and poor bioavailability => low risk of overdose (accidental or

intentional) Overdose and abuse possible due to opioid agonist effect Naloxone Opioid agonist with stronger affinity to opioid receptors than opioids Administration displaces opioids off receptors Naloxone is available for friends and loved ones of people with opioid dependence 200 participating pharmacies in Colorado

Part of harm reductions efforts in the state Module 3 Summary Tolerance: neurological adaptation in which sensitivity of opioid receptors decreases, requiring increasingly larger doses for the same drug effects. Opioid withdrawal: severe flu-like state, with duration and severity depending on drug of abuse and degree of physical dependence. Drug interacts with benzodiazepines, sedative hypnotics, cytochrome P450 3A4 drugs, antiretroviral agents, anti-seizure medications, and other opioids. Buprenorphine works! BH providers understand buprenorphine treatment.

[email protected] Mr. Brown 35 year old male with extensive history of heroin and other drugs. He was diagnosed with HIV a year ago, which he likely contracted due to unsafe needle use. Since his diagnosis he has continued to use heroin, though he has not injected. His medical provider is urging him to stop using heroin because it can interfere with his HIV treatment. He has previous inpatient detoxifications, which have ultimately failed.

Implementing Technology and Medication Assisted Treatment and Team Training in Rural Colorado Behavioral Health Provider Training Module 4: OUD Detection and Diagnosis Copyright 2018 Regents of the University of Colorado. All Rights Reserved. For permission to use content for purposes other than IT MATTTRs Practice Team Training, please contact [email protected]

Module Overview Screening and assessment of patients for OUD Importance of patient engagement Motivational Interviewing (MI) Why Use MI? Facilitate connecting with patients for effective screening and diagnosis Motivate patients to obtain treatment and make changes Effective in medical settings and associated with improved health outcomes

How is MI different from everything else? Recognizes the expertise of the patient on his/her own motivations Guides patient to examine and resolve ambivalence about problem Four Steps of MI 1) Building rapport with the patient 2) Focusing on the topic 3) Evoking or eliciting thoughts/emotions about the topic 4) Planning for change

Ms. Lopez 40 year old female with a history of generalized anxiety diagnosed with arthritis 5 years ago. She was started on opioids after failing NSAIDs. Throughout the years her daily dose has increased significantly and she is now taking hydrocodone and oxycodone. She has noticed that she feels ill whenever she does not take her medication and has even found herself stealing prescription opioids from her best friends medicine cabinet. She is concerned about her use and has been self-medicating with buprenorphine to reduce her use of hydrocodone and oxycodone.

SMART Goals Intention: What is it that patient wants to achieve? Specific Who? What? When? Where? Measurable How much? How often? How many? Attainable Is it achievable? Relevant Is it important to what patient wants to achieve?

Time-based By when? Screening for OUD Screening Instruments Use of an evidence-based screening tool can detect substance use problems more accurately than clinical judgment Even providers and practices experienced in diagnosing and treating substance use disorders can benefit from the use of formal screening instruments.

CAGE-AID Cut down Have you ever felt you ought to cut down on your drinking or drug use? Annoyed Have people annoyed you by criticizing your drinking or drug use? Guilty Have you ever felt bad or guilty about your drinking or drug use? Eye-opener Have you ever had a drink or used drugs first thing in the morning to steady your nerves or to get rid of a hangover?

Scoring: Of the 4 items, a "yes" answer to one item indicates a possible substance use disorder and a need for further testing. NIDA Quick Screen In the past year, how many times have you used the following? Drug Type Alcohol: Men: > 5 drinks/day Women: > 4 drinks/day Tobacco products

Misused prescription drugs Illegal drugs Never Once or Twice Monthly

Weekly Daily or almost Daily Other Screening Instruments Two-Item Conjoint Screening (TICS) Both alcohol and drug use. Detects current substance use, NOT a history of use. Questions can be integrated into a standard clinical interview. NIDA-Modified Alcohol, Smoking, and Substance Involvement Screening Test (NMASSIST) Further assess drug use after a positive NIDA Quick Screen.

Drug Abuse Screening Test-10 (DAST-10) Short version of the Drug Abuse Screening Test often used as a screening and diagnostic tool in primary care. AUDIT Brief alcohol screen often used in primary care. Current Opioid Misuse Measure (COMM) Identify patients with chronic pain taking opioids who have indicators of current aberrant drug-related behaviors. Screening Adolescents: Practice Tips Phrase questions so they are perceived as least threatening

Try making gentle assumptions "How often do you drink alcohol?" Address positive responses immediately, with further assessment, intervention, and discussion of possible referral or treatment, if indicated, rather than postponing to later in the appointment. Pharmacologic Treatment with Adolescents Pharmacologic therapy is recommended for adolescents with severe OUD. Buprenorphine is considered first line treatment. Most methadone clinics

cannot admit patients under 18 years old. Optimal length of time for medication treatment is not known. Teen Confidentiality Teens presenting with parents: Confidentiality is clinical decision of what should be shared with parents in context of parents already being aware of big picture Teens presenting without parents: Can consent at 15 in Colorado, though this does not guarantee confidentiality. Teens who refuse to involve parents: Explore reasons for excluding parents and reinforce help-seeking behavior, continue to discuss ways

of breaking the news to parents Screening Adolescents: CRAFFT Car Have you ever ridden in a car driven by someone (including yourself) who was "high" or had been using alcohol or drugs? Relax Do you ever use alcohol or drugs to relax, feel better about yourself, or fit in? Alone Do you ever use alcohol or drugs while you are by yourself or alone? Forget Do you ever forget things you did while using alcohol or drugs? Family/Friend Do your family or friends ever tell you that you should cut down on your drinking or drug use? Trouble Have you ever gotten into trouble while you were using alcohol or drugs?

Interpretation: Two or more positive items indicate the need for further assessment. Adolescent Risk Factors ADHD, conduct disorder, and sensation-seeking behavior Homelessness in youth and running away associated with greater risk of injected opioid use Red flags:

Marked change in physical health Deteriorating performance in school or job Dramatic change in personality, dress, or friends Involvement in serious delinquency or crimes HIV high-risk activities Serious psychological problems Signs and Symptoms of

OUD Physical Signs and Symptoms of Opioid Misuse GI problems Low blood pressure Decreased respiration rate Confusion Constipation Pupillary constriction Suppression of cough reflex

Dry mouth and nose Decreased libido and/or sexual dysfunction Irregular menses Irritation of nose lining Perforated nasal septum Abscesses, cellulitis, or dermatitis at injection sites Skin necrosis Tourniquet pigmentation

Psychosocial Signs and Symptoms of OUD Cravings Added criterion in DSM-5 diagnosis of OUD. In asking about craving, include thinking a lot about using, dreams about using, having thought of using opioids on your mind a lot. Behavioral Agitation, anxiety, anger, irritability, depression, insomnia, mood swings, weight changes

Family Marital problems (e.g., separation, divorce), abuse or violence, childrens behavioral problems, family members anxiety and depression Social Loss of long-standing friendships, spending time with other drug abusers, social isolation, loss of interest in regular activities

Work/School Missing work or school, poor performance, frequent job changes or relocations Legal Arrests, DUIs, theft, drug dealing. Legal problems are no longer diagnostic criterion. Financial Recent large debt, borrowing money from friends/relatives, selling possessions

Opioid Use Disorder Criteria (DSM-5) Opioids taken in larger amounts or longer period than intended Persistent desire or unsuccessful efforts to cut down or control opioid use Great deal of time spent in activities necessary to obtain, use, or recover from effects of opioids Craving/strong desire or urge to use (new to DSM-5) Recurrent use resulting in failure to fulfill major role obligations at work, school, or home

Opioid Use Disorder Criteria (DSM-5) Continued use despite persistent or recurrent social or interpersonal problems caused by or exacerbated by effects of opioids Important social, occupational, or recreational activities give up or reduced due to use Recurrent use in physically hazardous situations Use continued despite persistent or recurrent physical or psychological problem likely to have been caused or exacerbated by opioids Tolerance Do not apply if used appropriately Withdrawal

under medical supervision Treatment for those not regularly using opioids Some high-risk, opioid-abusing patients who do not meet diagnostic criteria, may be good candidates for buprenorphine maintenance. Certain patients who are not currently abusing opioid may also qualify for office-based opioid treatment. Inmate with a good prior treatment record with buprenorphine ("institutional abstinence") may be maintained on buprenorphine following release, if relapse is likely. ***Educate that opioid tolerance is now relatively lower, in

order to reduce their risk of overdose.*** Assess Patients for Office Based Treatment Once you identify OUD in a patient: Assess patient attitudes Motivate patients for change Determine appropriate interventions Determine duration, pattern, and severity of opioid use disorder

Determine level of tolerance Gather history of previous attempts to use agonist therapy Gather history of previous attempts to quit Assess current opioid use and withdrawal status Determine history of withdrawal Refer to a MAT prescriber/provider/program in your community Co-Occurring Conditions Increased Risk of Mental Illness

Dual diagnosis of OUD with other forms of mental illness is common. Pre-existing psychiatric disorders are associated with increased risk of opioid misuse Mood disorders: depressive disorder, bipolar I disorder, Anxiety disorders: panic and generalized anxiety disorders Opioid misuse more likely to lead to full OUD when these disorders are present. Opioid misuse also associated with later development of mental illness. Depression: Prevalence Most prevalent mood disorder

among patients with OUD. 44% to 54% lifetime depression Depression: Impact on MAT Patients with vs patients without comorbid depression: Less likely to respond well to treatment

More likely to relapse to opioid use Respond well to psychiatric intervention Sometimes depression can be a manifestation of a substance use disorder and can remit rapidly after patients cease misuse Screening instruments:

Patient Health Questionnaire Hospital Anxiety and Depression Scales Geriatric Depression Scale Edinburg Postnatal Depression Anxiety Disorders: Prevalence Lifetime prevalence OUD (abuse and dependence): 36% Opioid dependence: 61% Generalized anxiety disorder

Opioid dependence: 22% Phobia Opioid dependence: 33% Anxiety Disorders: Impact on MAT Poorer quality of life Greater likelihood of treatment dropout Abuse of other substances (e.g., benzodiazepines) Routine treatment with pharmacotherapy is appropriate Caution needed regarding use of benzodiazepines given risk of respiratory

depression and lethality Posttraumatic Stress Disorder: Prevalence Common among people with substance use disorders. Most common among OUD relative to other substance use disorders. 40.6% of people with drug dependence reported symptoms of PTSD and were diagnosed with PTSD. Posttraumatic Stress Disorder: Impact on MAT

PTSD = severity of drug problems PTSD symptoms can overlap with those of opioid withdrawal E.g., hypervigilance, exacerbated startle response, insomnia Opioid use may be a kind of self-medication for PTSD Good outcomes for OUD, but poor outcomes for co-occurring PTSD Treatment for PTSD should be integrated with treatment for OUD. Suicidality: Prevalence Almost half of opioid users have a past suicide attempt. Suicide among opioid users is approximately a third higher than in the

general population. Up to 7% of those with opioid users die from suicide each year. 20% of suicides are associated with opioids (heroin and prescription pain killers) In a matter of 15 years (1999 to 2014), suicide with opioid poisoning increased from 2% to 4%. Suicidality: Impact of Treatment and MAT Impact of treatment: Treatment decreases risk of suicidal ideation and attempts.

Assessment Assess relative risk of committing suicide when suicidality is reported or suspected. Assess whether patient wants to kill himself/herself, has access to lethal means of suicide, and has a plan. Consider screens like the Columbia-Suicide Severity Rating Scale. Personality Disorders: Prevalence Lifetime prevalence: 50% More than 4x the prevalence than the general population Borderline personality disorder ~50%

Antisocial personality disorder ~40% Personality Disorders: Impact on MAT Increased difficulty of treating OUD Inflexibility and maladaptive thoughts/behaviors can strain doctor-patient relationship (e.g., impulsivity, emotional reactivity) May not respond as well Are less likely to complete treatment

Are more prone to relapse to opioid misuse after successful treatment Consider the following: Additional time learning a patients individual challenges Additional care in communications and efforts to build trust Referring patients to a higher level of care if above precautions are not possible or are ineffective ADHD More careful instructions when instructing patients on correct buprenorphine usage and dosing, considering the patients attention span Additional treatment structure

Additional follow-up phone calls during induction and stabilization Additional psychosocial support (e.g., 12-step program) Polysubstance Use Cocaine use is most common among patients with addiction to heroin 75% concurrent use Alcohol can be abused by licit and illicit drug users. Benzodiazepines are lethal with opioids Goal should be to decrease or discontinue use of benzodiazepines BHPs can help patients address anxiety in other ways

Marijuana is commonly used because it helps manage withdrawal symptoms. Differentiating Between Opioid-Induced vs. Opioid Independent Psychiatric Disorders Order of Onset Psychiatric disorder not a cause of opioid misuse if it developed after the patient began using opioids. Family History

Family history of mental illness increases likelihood that mental illness is independent of opioid misuse. Symptoms During Abstinence Psychiatric disorders that persist during periods of abstinence (from both opioids and all other substances of abuse) are much more likely to be independent of opioid misuse.

Treatment of Induced Psychiatric Disorders Resolve once opioid use stops (especially depression) Stability as first therapeutic step Psychiatric intervention necessary only in severely affected patients (i.e., suicidal patients) Reverse treatment sequence may be necessary, i.e., stabilization of psychiatric illness before buprenorphine treatment Module 4 Summary Motivational interviewing is effective. It can facilitate connecting with

patient and can help enhance motivation to seek treatment. Use of screening instruments is valuable. Buprenorphine treatment is indicated for moderate to severe OUD. Dual diagnosis of OUD with other forms of mental illness is common and can affect treatment. BH providers can help address mental health concerns underlying OUD. [email protected]

Recently Viewed Presentations

  • Cave Safety Standards James Goodbar Senior Cave/Karst Specialist

    Cave Safety Standards James Goodbar Senior Cave/Karst Specialist

    Cave Safety Standards . The Standards consist of: Cave Safety Guidelines . Search and Rescue (SAR) Pre-Planning. Risk Assessment (DOI), Job Hazard Analysis (DOA) You Will Learn: Where and to Whom the Standards Apply, What the Standards Require, How they...
  • Darwin India Pollinators PME - InSpiral Pathways

    Darwin India Pollinators PME - InSpiral Pathways

    The Power of Appreciative InquirySolving Problems by Looking at What's Going Right & it possible use for the Centre for Pollination Studies. Dr John Mauremootoo. The original 1987 article was written by David Cooperrider and Suresh Srivastva. Thestudy of what...
  • Agenda February 8, 2018  Governance Council Charge &

    Agenda February 8, 2018 Governance Council Charge &

    Succession Planning Input Sessions. Please plan to attend one of the following sessions to learn more about succession planning recommendations and to provide input into the process.
  • Seeking synergy: The need for research at the literacy ...

    Seeking synergy: The need for research at the literacy ...

    Interactive, face to face. ... MODE CONTINUUM "Children have to learn to use language for a range of purposes and in a range of cultural and situational contexts" ... Seeking synergy: The need for research at the literacy/ numeracy interface
  • Production and Operations Management: Manufacturing and Services

    Production and Operations Management: Manufacturing and Services

    Demand Management and Forecasting Demand Management Qualitative Forecasting Methods Simple & Weighted Moving Average Forecasts Exponential Smoothing Simple Linear Regression Web-Based Forecasting Demand Management Independent Demand: What a firm can do to manage it?
  • Endocrine System - Effingham County Schools / Overview

    Endocrine System - Effingham County Schools / Overview

    Endocrine System Hormones and the glands that send them The Endocrine System Controls many body functions exerts control by releasing special chemical substances into the blood called hormones Hormones affect other endocrine glands or body systems Major Function - Control...
  • Shedding Light on An Fda Visit - Usc

    Shedding Light on An Fda Visit - Usc

    SHEDDING LIGHT ON ANFDA VISIT. Joyce Nancarrow Tull, MSN, RN, CCRP. ... Keep notes of the lessons learned; that's where the BIMO checklist came from! ... STOP when the question is fully answered. KEY GUIDANCE, CON'T.
  • Foundation 1 - Discovering Astronomy

    Foundation 1 - Discovering Astronomy

    Analyzing The Properties of Light Visible light is only one type of electromagnetic radiation emitted by stars Slide 15 Slide 16 SOFIA - the Stratospheric Observatory for Infrared Astronomy Observations at other wavelengths are revealing previously invisible sights Slide 19...